巨子生物(02367)早盘涨超5%，截至发稿，涨4.44%，报75.3港元，成交额4.22亿港元。

消息面上，国货美妆头部品牌可复美近日深陷“EGF添加门”舆论漩涡。陕西省药监局针对近日媒体对可复美品牌“检出违禁添加表皮生长因子EGF”的报道做出通报，多批次可复美产品均未检出EGF。据悉，可复美为巨子生物的核心品牌，2024年销售收入达45.42亿元，同比增长62.9%，占公司总营收的82%。

此外，巨子生物近期宣布，拟折让约9.50%先旧后新配股，最高净筹约22.94亿港元，拟用于核心业务的发展及生态圈布局，包括品牌推广、市场营销、品类扩展、海外业务及研发投入；以及补充流动资金及作一般企业用途。花旗发布研报称，鉴于较大的折让，预期短期内该股的股价将会承压。尽管如此，巨子生物的盈利前景依然稳健。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.